# Contango Silver & Gold Inc.: financial statements, quarterly

CTGO · NYSE · CIK 1502377 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ctgo.md) · [Financials](/companies/ctgo/financials.md) · [Filings](/companies/ctgo/filings.md) · [Insiders](/companies/ctgo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ctgo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(9.6)](/filings/0000950170-24-126724.md) | [(5.6) d](/filings/0000950170-25-039841.md) | [(2.9)](/filings/0000950170-25-071503.md) | [(3.1)](/filings/0000950170-25-108075.md) | [22.7](/filings/0001193125-25-280434.md) | [9.5 d](/filings/0001193125-26-107141.md) | [19.3](/filings/0001193125-26-222855.md) | [23.0](/filings/0001193125-26-349539.md) | [25.0](/filings/0001193125-25-280434.md) | [1.8 d](/filings/0001193125-26-107141.md) | [4.8](/filings/0001193125-26-222855.md) | [(8.5)](/filings/0001193125-26-349539.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0000950170-24-126724.md) | [0.0 d](/filings/0000950170-25-039841.md) | [0.0](/filings/0000950170-25-071503.md) | [0.0](/filings/0000950170-25-108075.md) | [0.7](/filings/0001193125-25-280434.md) | [(0.8) d](/filings/0001193125-26-107141.md) | [0.2](/filings/0001193125-26-222855.md) | [(0.1)](/filings/0001193125-26-349539.md) | [(0.1)](/filings/0001193125-25-280434.md) | [0.2 d](/filings/0001193125-26-107141.md) | [(0.0)](/filings/0001193125-26-222855.md) | [(1.9)](/filings/0001193125-26-349539.md) |
| Net income | $m | [(13.1)](/filings/0000950170-24-126724.md) | [(27.6) d](/filings/0000950170-25-039841.md) | [(20.5)](/filings/0000950170-25-071503.md) | [(18.5)](/filings/0000950170-25-108075.md) | [(9.7)](/filings/0001193125-25-280434.md) | [10.7 d](/filings/0001193125-26-107141.md) | [(22.5)](/filings/0001193125-26-222855.md) | [15.9](/filings/0001193125-26-349539.md) | [(5.4)](/filings/0001193125-25-280434.md) | [(24.1) d](/filings/0001193125-26-107141.md) | [(14.3)](/filings/0001193125-26-222855.md) | [4.8](/filings/0001193125-26-349539.md) |
| Diluted EPS | $ per share | [(1.47)](/filings/0000950170-24-126724.md) | not reported | [(2.14)](/filings/0000950170-25-071503.md) | [(1.90)](/filings/0000950170-25-108075.md) | [(0.81)](/filings/0001193125-25-280434.md) | not reported | [(1.88)](/filings/0001193125-26-222855.md) | [1.24](/filings/0001193125-26-349539.md) | [(0.44)](/filings/0001193125-25-280434.md) | not reported | [(0.83)](/filings/0001193125-26-222855.md) | [0.14](/filings/0001193125-26-349539.md) |
| Basic EPS | $ per share | [(1.47)](/filings/0000950170-24-126724.md) | not reported | [(2.14)](/filings/0000950170-25-071503.md) | [(1.90)](/filings/0000950170-25-108075.md) | [(0.81)](/filings/0001193125-25-280434.md) | not reported | [(1.88)](/filings/0001193125-26-222855.md) | [1.26](/filings/0001193125-26-349539.md) | [(0.44)](/filings/0001193125-25-280434.md) | not reported | [(0.83)](/filings/0001193125-26-222855.md) | [0.14](/filings/0001193125-26-349539.md) |

- Revenue: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [18.5](/filings/0001437749-23-031883.md) | [15.5](/filings/0000950170-25-039841.md) | [7.6](/filings/0000950170-24-059574.md) | [24.1](/filings/0000950170-24-096321.md) | [36.2](/filings/0000950170-24-126724.md) | [20.1](/filings/0001193125-26-107141.md) | [35.0](/filings/0000950170-25-071503.md) | [36.5](/filings/0000950170-25-108075.md) | [107](/filings/0001193125-25-280434.md) | [64.8](/filings/0001193125-26-349539.md) | [97.5](/filings/0001193125-26-222855.md) | [89.0](/filings/0001193125-26-349539.md) |
| Current assets | $m | [20.1](/filings/0001437749-23-031883.md) | [16.9](/filings/0000950170-25-039841.md) | [9.0](/filings/0000950170-24-059574.md) | [25.6](/filings/0000950170-24-096321.md) | [37.5](/filings/0000950170-24-126724.md) | [22.1](/filings/0001193125-26-107141.md) | [37.1](/filings/0000950170-25-071503.md) | [38.9](/filings/0000950170-25-108075.md) | [108](/filings/0001193125-25-280434.md) | [68.3](/filings/0001193125-26-349539.md) | [102](/filings/0001193125-26-222855.md) | [95.0](/filings/0001193125-26-349539.md) |
| Total assets | $m | [54.9](/filings/0001437749-23-031883.md) | [58.6](/filings/0000950170-25-039841.md) | [66.2](/filings/0000950170-24-059574.md) | [93.6](/filings/0000950170-24-096321.md) | [158](/filings/0000950170-24-126724.md) | [134](/filings/0001193125-26-107141.md) | [147](/filings/0000950170-25-071503.md) | [153](/filings/0000950170-25-108075.md) | [218](/filings/0001193125-25-280434.md) | [172](/filings/0001193125-26-349539.md) | [496](/filings/0001193125-26-222855.md) | [497](/filings/0001193125-26-349539.md) |
| Current liabilities | $m | [5.0](/filings/0001437749-23-031883.md) | [13.1](/filings/0000950170-25-039841.md) | [32.7](/filings/0000950170-24-059574.md) | [50.5](/filings/0000950170-24-096321.md) | [80.5](/filings/0000950170-24-126724.md) | [75.8](/filings/0001193125-26-107141.md) | [91.0](/filings/0000950170-25-071503.md) | [82.1](/filings/0000950170-25-108075.md) | [95.2](/filings/0001193125-25-280434.md) | [76.3](/filings/0001193125-26-349539.md) | [80.2](/filings/0001193125-26-222855.md) | [89.4](/filings/0001193125-26-349539.md) |
| Total liabilities | $m | [43.8](/filings/0001437749-23-031883.md) | [73.1](/filings/0000950170-25-039841.md) | [100](/filings/0000950170-24-059574.md) | [132](/filings/0000950170-24-096321.md) | [169](/filings/0000950170-24-126724.md) | [133](/filings/0001193125-26-107141.md) | [168](/filings/0000950170-25-071503.md) | [156](/filings/0000950170-25-108075.md) | [170](/filings/0001193125-25-280434.md) | [147](/filings/0001193125-26-349539.md) | [175](/filings/0001193125-26-222855.md) | [165](/filings/0001193125-26-349539.md) |
| Long-term debt | $m | [32.9](/filings/0001437749-23-031883.md) | [36.8](/filings/0000950170-25-039841.md) | [35.4](/filings/0000950170-24-059574.md) | [44.7](/filings/0000950170-24-096321.md) | [39.0](/filings/0000950170-24-126724.md) | [26.4](/filings/0001193125-26-107141.md) | [31.4](/filings/0000950170-25-071503.md) | [31.0](/filings/0000950170-25-108075.md) | [30.6](/filings/0001193125-25-280434.md) | [29.9](/filings/0001193125-26-349539.md) | [21.0](/filings/0001193125-26-222855.md) | [19.5](/filings/0001193125-26-349539.md) |
| Current portion of debt | $m | [2.0](/filings/0001437749-23-031883.md) | [7.9](/filings/0000950170-25-039841.md) | [21.7](/filings/0000950170-24-059574.md) | [29.9](/filings/0000950170-24-096321.md) | [34.9](/filings/0000950170-24-126724.md) | [42.6](/filings/0001193125-26-107141.md) | [24.7](/filings/0000950170-25-071503.md) | [17.5](/filings/0000950170-25-108075.md) | [11.5](/filings/0001193125-25-280434.md) | [4.0](/filings/0001193125-26-349539.md) | [12.0](/filings/0001193125-26-222855.md) | [12.6](/filings/0001193125-26-349539.md) |
| Shareholders' equity | $m | [11.0](/filings/0000950170-24-126724.md) | [(14.5)](/filings/0001193125-26-107141.md) | [(34.0)](/filings/0000950170-25-108075.md) | [(37.9)](/filings/0001193125-25-280434.md) | [(10.2)](/filings/0001193125-25-280434.md) | [1.3](/filings/0001193125-26-349539.md) | [(20.5)](/filings/0001193125-26-349539.md) | [(2.4)](/filings/0001193125-26-349539.md) | [47.8](/filings/0001193125-25-280434.md) | [25.1](/filings/0001193125-26-349539.md) | [322](/filings/0001193125-26-349539.md) | [332](/filings/0001193125-26-349539.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(3.6)](/filings/0001437749-23-031883.md) | [(5.9) d](/filings/0000950170-25-039841.md) | [(4.4)](/filings/0000950170-25-071503.md) | [(2.4) d](/filings/0000950170-25-108075.md) | [17.5 d](/filings/0001193125-25-280434.md) | [(9.9) d](/filings/0001193125-26-107141.md) | [28.6](/filings/0001193125-26-222855.md) | [8.4 d](/filings/0001193125-26-349539.md) | [23.3 d](/filings/0001193125-25-280434.md) | [(34.5) d](/filings/0001193125-26-107141.md) | [(49.6)](/filings/0001193125-26-222855.md) | [(0.7) d](/filings/0001193125-26-349539.md) |
| Capital expenditure | $m | [0.0](/filings/0001437749-23-031883.md) | [0.0 d](/filings/0000950170-24-031469.md) | [0.0](/filings/0000950170-24-059574.md) | [(0.0) d](/filings/0000950170-24-096321.md) | [0.0 d](/filings/0000950170-24-126724.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2023 (2022-12-30) | Q3 FY2023 (2023-03-31) | Q4 FY2023 (2023-06-30) | Q1 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [6.8](/filings/0001437749-23-002590.md) | [7.2](/filings/0000950170-24-059574.md) | [7.5](/filings/0000950170-24-096321.md) | [8.9](/filings/0000950170-24-126724.md) | [9.6](/filings/0000950170-25-071503.md) | [9.8](/filings/0000950170-25-108075.md) | [12.0](/filings/0001193125-25-280434.md) | [12.0](/filings/0001193125-26-222855.md) | [12.3](/filings/0001193125-26-349539.md) | [12.4](/filings/0001193125-25-280434.md) | [17.2](/filings/0001193125-26-222855.md) | [33.1](/filings/0001193125-26-349539.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 33,440,691 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349539.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.